Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 7/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.65 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.65 |
| ▸ | F2 | P00734 | 1/20 | 0.61 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.56 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.49 |
| ▸ | KRAS | P01116 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25552773 | 0.93 | TGM2 (0.60) | P2RY2P2RY4P2RY6F2RNASEL | |
| SCHEMBL23477443 | 0.91 | FUT5 (0.54) | P2RY2P2RY4P2RY6F2RNASEL | |
| SCHEMBL23477028 | 0.90 | FUT5 (0.58) | P2RY2P2RY4P2RY6F2RNASEL | |
| SCHEMBL24771772 | 0.89 | RNASEL (0.56) | RNASELFUT5TGM2 | |
| SCHEMBL23477159 | 0.89 | RNASEL (0.56) | RNASELFUT5TGM2 | |
| SCHEMBL19448916 | 0.88 | TGM2 (0.61) | P2RY2P2RY4P2RY6RNASELFUT5 | |
| SCHEMBL21648046 | 0.88 | TGM2 (0.61) | P2RY2P2RY4P2RY6RNASELFUT5 | |
| SCHEMBL23477132 | 0.87 | FUT5 (0.60) | P2RY2P2RY4P2RY6F2RNASEL | |
| SCHEMBL29589660 | 0.86 | P2RY2 (0.66) | P2RY2P2RY4P2RY6F2RNASEL | |
| SCHEMBL20762956 | 0.85 | TGM2 (0.65) | P2RY2P2RY4P2RY6RNASELFUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | P2RY2 1477/4885P2RY4 1086/4885P2RY6 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.